

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

Brilliant Violet 510(TM) anti-mouse CD4

RRID:AB_2561388

Type: Antibody

Proper Citation

BioLegend Cat# 100553, RRID:AB_2561388

Antibody Information

URL: http://antibodyregistry.org/AB_2561388

Proper Citation: BioLegend Cat# 100553, RRID:AB_2561388

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_2561388

Vendor: BioLegend

Catalog Number: 100553

Alternative Catalog Numbers: 100559

Record Creation Time: 20250819T232628+0000

Record Last Update: 20250820T052055+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-mouse CD4.

No alerts have been found for Brilliant Violet 510(TM) anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Fan Z, et al. (2026) Programmable-bacteria-macrophage backpacks for enhanced solid tumor therapy via mechanobiological interplay. Cell reports. Medicine, 102924.

Yao J, et al. (2026) Activating an interleukin 4-FLT3-STAT6 axis in multipotent progenitors restores lymphopoiesis in inflammation and aging. Immunity, 59(7), 1843.

Lambert F, et al. (2025) Antibody-mediated TGF- β 1 activation for the treatment of diseases caused by deleterious T cell activity. Cell reports, 44(8), 116061.

Dong S, et al. (2025) 3-in-one PD-1CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential. iScience, 28(11), 113677.

Kandasamy M, et al. (2025) Glycogen synthase kinase-3 is essential for Treg development and function. Cell reports, 44(9), 116256.

Köhne M, et al. (2025) Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. Cell reports, 44(7), 115866.

Marchingo JM, et al. (2025) PIM kinase control of CD8 T cell protein synthesis and cell trafficking. eLife, 13.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. Cancer cell, 43(8), 1512.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8+ T cells. Immunity, 58(10), 2472.

Li X, et al. (2024) MCRS1 sensitizes T cell-dependent immunotherapy by augmenting MHC-I expression in solid tumors. The Journal of experimental medicine, 221(12).

Xia M, et al. (2024) Elevated IL-22 as a result of stress-induced gut leakage suppresses septal neuron activation to ameliorate anxiety-like behavior. Immunity.

Gao G, et al. (2023) Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine, 91, 104533.

Jin WJ, et al. (2023) NK cells propagate T cell immunity following in situ tumor vaccination. Cell reports, 42(12), 113556.

Cao W, et al. (2023) TRIB2 safeguards naive T cell homeostasis during aging. Cell reports, 42(3), 112195.

Wu Z, et al. (2023) Pericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer. EMBO reports, 24(4), e56524.

Toutouchi NS, et al. (2021) Human Milk Oligosaccharide 3'-GL Improves Influenza-Specific Vaccination Responsiveness and Immunity after Deoxynivalenol Exposure in Preclinical Models. Nutrients, 13(9).

Dikiy S, et al. (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity, 54(5), 931.

Renoux F, et al. (2020) The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development. Cell reports, 31(13), 107826.

Miragaia RJ, et al. (2019) Single-Cell Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation. Immunity, 50(2), 493.

Hoyer FF, et al. (2019) Tissue-Specific Macrophage Responses to Remote Injury Impact the Outcome of Subsequent Local Immune Challenge. Immunity, 51(5), 899.